Research Enhancement Award Program at the Providence Veterans Affairs Medical Center, Providence, Rhode Island, United States of America.
PLoS One. 2011 Apr 26;6(4):e19298. doi: 10.1371/journal.pone.0019298.
Cardiovascular disease is the leading cause of mortality among patients with serious mental illness (SMI) and the prevalence of metabolic syndrome--a constellation of cardiovascular risk factors--is significantly higher in these patients than in the general population. Metabolic monitoring among patients using second generation antipsychotics (SGAs)--a risk factor for metabolic syndrome--has been shown to be inadequate despite the release of several guidelines. However, patients with SMI have several factors independent of medication use that predispose them to a higher prevalence of metabolic syndrome. Our study therefore examines monitoring and prevalence of metabolic syndrome in patients with SMI, including those not using SGAs.
We retrospectively identified all patients treated at a Veterans Affairs Medical Center with diagnoses of schizophrenia, schizoaffective disorder or bipolar disorder during 2005-2006 and obtained demographic and clinical data. Incomplete monitoring of metabolic syndrome was defined as being unable to determine the status of at least one of the syndrome components. Of the 1,401 patients included (bipolar disorder: 822; schizophrenia: 222; and schizoaffective disorder: 357), 21.4% were incompletely monitored. Only 54.8% of patients who were not prescribed SGAs and did not have previous diagnoses of hypertension or hypercholesterolemia were monitored for all metabolic syndrome components compared to 92.4% of patients who had all three of these characteristics. Among patients monitored for metabolic syndrome completely, age-adjusted prevalence of the syndrome was 48.4%, with no significant difference between the three psychiatric groups.
Only one half of patients with SMI not using SGAs or previously diagnosed with hypertension and hypercholesterolemia were completely monitored for metabolic syndrome components compared to greater than 90% of those with these characteristics. With the high prevalence of metabolic syndrome seen in this population, there appears to be a need to intensify efforts to reduce this monitoring gap.
心血管疾病是严重精神疾病(SMI)患者死亡的主要原因,代谢综合征——一组心血管危险因素——在这些患者中的患病率明显高于普通人群。尽管发布了多项指南,但第二代抗精神病药物(SGAs)——代谢综合征的一个危险因素——的患者代谢监测仍不充分。然而,除了药物使用外,SMI 患者还有一些独立的因素,使他们更容易患上代谢综合征。因此,我们的研究检查了 SMI 患者(包括未使用 SGAs 的患者)的代谢综合征监测和患病率。
我们回顾性地确定了 2005-2006 年在退伍军人事务医疗中心接受精神分裂症、分裂情感障碍或双相情感障碍诊断的所有患者,并获得了人口统计学和临床数据。代谢综合征监测不完整的定义为无法确定至少一个综合征组成部分的状态。在纳入的 1401 名患者中(双相情感障碍:822 例;精神分裂症:222 例;分裂情感障碍:357 例),21.4%的患者监测不完整。与具有所有三种特征的患者相比,未开处方 SGA 且无高血压或高胆固醇血症既往诊断的患者仅监测了所有代谢综合征成分的 54.8%。在完全监测代谢综合征的患者中,该综合征的年龄调整患病率为 48.4%,三组精神疾病患者之间无显著差异。
与具有这些特征的患者相比,未使用 SGA 或既往诊断为高血压和高胆固醇血症的 SMI 患者中,只有一半的患者完全监测了代谢综合征成分。在该人群中,代谢综合征的高患病率表明,似乎需要加强努力,减少这种监测差距。